Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Second round of radiation may help fight recurrent brain cancer

NCT ID NCT06344130

First seen Jan 10, 2026 · Last updated Jun 22, 2026 · Updated 25 times

Summary

This early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, depending on the dose level. The main goal is to find a safe schedule, while also tracking how long the tumor stays under control and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Radiation therapy

What this could lead to

If successful, this could establish a safer way to give additional radiation to people whose brain tumor has returned, potentially extending survival.

What could go wrong

This is a very early phase 1 trial with only 28 participants, so it is primarily testing safety, not effectiveness. The benefits are uncertain, and there is a risk of brain damage from extra radiation.

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) glioblastoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.